SecBot SecBot
SECBOTREPLAY Home › Report › NVAX

NVAX · Novavax reported Q3 2026 total revenue of $68M, a 3% decline from $70M…

NOVAVAX INC · 8-K filed Nov 5, 2026 at 08:08 ET

At the news

BULLISHIMPACT 6/10

8-K filed Nov 5, 2026 at 08:08 ET

Novavax reported Q3 2026 total revenue of $68M, a 3% decline from $70M in Q3 2025, and a GAAP net loss of $31M (improved from a $202M loss a year ago). The company raised its full-year 2026 Adjusted Total Revenue guidance by $145M at the midpoint to $385M-$415M, driven by a $125M milestone earned from Sanofi's Phase 3 influenza-COVID-19 combination vaccine trial initiation. The net loss narrowed sharply due to reduced R&D and SG&A expenses.

  • Q3 2026 total revenue $68M, down 3% YoY from $70M
  • Product sales $26M, up 91% YoY from $13M
  • Licensing, royalties and other revenue $43M, down 25% YoY from $57M
  • GAAP net loss $31M, improved from net loss of $202M in Q3 2025

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access